Fatal recurrent VTE after anticoagulant treatment for unprovoked VTE: a systematic review

Sake J. van der Wall [1], Liselotte M. van der Pol[1], Yvonne M. Ende-Verhaar[1], Suzanne C. Cannegieter [2], Sam Schulman[3], Paolo Prandoni[4], Marc Rodger[5], Menno V. Huisman[1] and Frederikus A. Klok [1]

Affiliations: [1]Dept of Thrombosis and Haemostasis, Leiden University Medical Centre, Leiden, The Netherlands. [2]Dept of Clinical Epidemiology, Leiden University Medical Centre, Leiden, The Netherlands. [3]Dept of Medicine and Thrombosis and Atherosclerosis Research Institute, McMaster University, Hamilton, ON, Canada. [4]Arianna Foundation on Anticoagulation, Bologna, Italy. [5]Division of Haematology, Ottawa Hospital, Ottawa, ON, Canada.

Correspondence: Sake J. van der Wall, Dept of Thrombosis and Haemostasis, Leiden University Medical Centre, Albinusdreef 2, 2300 RC Leiden, The Netherlands. E-mail: s.j.van_der_wall@lumc.nl

ABSTRACT Current guidelines recommend long-term anticoagulant therapy in patients with unprovoked venous thromboembolism (VTE). The risk of fatal recurrent VTE after treatment discontinuation (*versus* that of fatal bleeding during anticoagulation) is of particular relevance in the decision to continue or stop anticoagulation after the first 3 months. Our primary aim was to provide a point-estimate of the yearly rate of fatal recurrent VTE and VTE case-fatality rate in patients with unprovoked VTE after anticoagulation cessation. Data were extracted from both randomised controlled trials and observational studies published before May 1, 2017. The pooled fatality rates were calculated using a random-effects model. 18 studies with low-to-moderate bias were included in the primary analysis, totalling 6758 patients with a median (range) follow-up duration of 2.2 (1–5) years. After anticoagulation cessation, the weighted pooled rate of VTE recurrence was 6.3 (95% CI 5.4–7.3) per 100 patient-years and the weighted pooled rate of fatal recurrent VTE was 0.17 (95% CI 0.047–0.33) per 100 patient-years, for a case-fatality rate of 2.6% (95% CI 0.86–5.0). These numbers are a solid benchmark for comparison to the risks associated with long-term anticoagulation treatment for the decision on the optimal duration of treatment of patients with unprovoked VTE.

Introduction

The risk of recurrent venous thromboembolism (VTE), which includes deep vein thrombosis (DVT) and pulmonary embolism (PE) persists after cessation of anticoagulant treatment and is particularly high among patients with unprovoked VTE [1–3]. Consequently, treatment guidelines recommend continuation of anticoagulant therapy beyond the first 3 months in patients with unprovoked VTE without high risk for major bleeding [4–6]. This recommendation is based on weighing the risk of recurrent VTE after

anticoagulant treatment cessation against the risk of major bleeding during ongoing treatment. For the individual patient, the risk of fatal recurrent VTE *versus* that of fatal bleeding is of particular relevance when making the decision to prolong treatment or not.

The case-fatality rate of major bleeding events during long-term vitamin K antagonist (VKA) treatment has been estimated to be as high as 9–13%, with a yearly rate of fatal bleeding varying between 0.2% and 1.5% [7, 8]. Importantly, this bleeding risk was found to decrease considerably with the introduction of direct oral anticoagulants (DOACs), which are associated with lower rates of intracranial and fatal bleeding than VKA, while non-inferiority was shown with regard to risk of recurrent VTE [9].

The case-fatality rate of recurrent VTE after cessation of anticoagulant therapy has previously been shown to vary between 3.6% and 5.1% in a mixed cohort of patients with both provoked and unprovoked VTE, with a yearly risk of fatal recurrence ranging between 0.4% and 0.5% [7, 10]. To date, these exact numbers are unknown for patients with unprovoked VTE, although this is the patient category for whom this knowledge is most relevant [4, 5]. Therefore, we conducted a systematic review and meta-analysis of the literature to provide an accurate point-estimate of the case-fatality rate of recurrent VTE as well as a yearly rate of fatal recurrences after anticoagulation cessation in patients with a first unprovoked VTE.

Methods
Data sources and literature search
A systematic literature search was conducted for all relevant publications in PubMed, Embase, Web of Science and the Cochrane Library in May 2017. The subject headings and/or keywords of our search strategy comprised "venous thromboembolism", "pulmonary embolism", "deep venous thrombosis", "anticoagulation" and "recurrence" and were database-specifically translated (online supplementary material).

Study selection and data extraction
Initial results were screened for relevant titles and abstracts by two independent reviewers (SJ and LM). This process was performed in duplicate and disagreements were independently resolved by consensus or by a third reviewer (FA). Studies were included if 1) consecutive patients with objectively confirmed symptomatic DVT or PE were prospectively enrolled (proximal DVT diagnosed in case of evidence of thrombosis in the popliteal or more proximal veins on compression ultrasonography or contrast venography and a diagnosis of PE based on at least one subsegmental filling defect on computed tomography pulmonary angiography (CTPA), high-probability ventilation/perfusion lung scan (V'/Q') or abnormal pulmonary angiography; 2) patients were subject to dedicated follow-up for symptomatic recurrent VTE and such events were objectively confirmed; 3) the initial anticoagulation treatment (with VKA or DOAC) was continued for $\geqslant$3 months and the follow-up period extended for $\geqslant$3 months after the anticoagulation therapy was discontinued; 4) fatal VTE events during follow-up after treatment cessation were reported (PE and/or DVT); and 5) $\geqslant$100 patients were included. Only full-text publications in the English language were reviewed for potential inclusion. There was no restriction on publication year.

After selection of all relevant articles, two reviewers (SJ and LM) independently extracted data on first author's name, year of publication, design (prospective/retrospective), number of patients included, age, initial anticoagulation treatment, the total duration of follow-up after cessation of treatment, proportion of unprovoked VTE at baseline (PE/DVT), case-fatality rate of recurrent VTE during follow-up after anticoagulant discontinuation (PE/DVT) and overall mortality during follow-up, as reported by the authors. The authors of publications with missing data were approached by email at least twice, 2 weeks apart. The PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) statement for reporting systematic reviews and meta-analysis was used for this study [11].

Study objectives
The primary objective was to determine the case-fatality rate of recurrent VTE after anticoagulation cessation following a first unprovoked VTE diagnosis, as well as the yearly rate of fatal VTE recurrences from selected studies with low to moderate bias. The secondary aims were to determine the overall rate of fatal VTE for all available studies, including those with a high risk of bias, and to differentiate between 1) enrolment periods, comparing studies that started enrolment before and after January 1, 2000 (if reported); 2) cohort studies and randomised controlled trials (RCTs); 3) studies with a follow-up duration that was shorter *versus* longer than 2.5 years; 4) patients who initially presented with DVT *versus* unprovoked PE; and 5) different definitions of fatal VTE that were applied.

Study outcomes and definitions
Recurrent PE was predefined as a new intraluminal filling defect on pulmonary angiography or CTPA, a new high-probability perfusion defect on V'/Q' scan or any new defects after earlier normalisation of the scan [12].

Recurrent DVT was defined as new noncompressibility by ultrasonography of the common femoral and/or popliteal vein, noncompressibility of a previously normalised vein segment or a pronounced increase in vein diameter (⩾4 mm) of a previously noncompressible venous segment [12]. Patients with both index DVT and PE were classified as patients with PE when fatal rates were reported separately for this subgroup. Fatal recurrent VTE was predefined as PE diagnosed by autopsy, high-probability V'/Q' scan, a new intraluminal filling defect detected on pulmonary angiography, computed tomography (CTPA) or venography prior to death or a high clinical suspicion as judged by the investigators of the individual studies. For each study, the definition of unprovoked VTE was evaluated *post hoc* and compared to criteria provided by the scientific and standardisation committee of the International Society on Thrombosis and Haemostasis (ISTH) [13].

Risk of bias

Two authors (SJ and LM) independently evaluated the risk of bias at a study level in accordance with the Cochrane Collaboration's tool for assessing risk of bias and the PRISMA statement [11, 14]. We focused on the following criteria. 1) Prespecified protocol; 2) clear description of inclusion and exclusion criteria; 3) adequate anticoagulation treatment prior to cessation according to international standards; 4) clear description of follow-up after anticoagulation cessation; 5) clear definitions provided of unprovoked and fatal VTE; 6) loss to follow-up; 7) adjudication of outcomes; and 8) assessment of primary end-point in all patients. Disagreements were resolved through discussion with a third author (FA).

Statistical analyses

Case-fatality rates of each study were calculated by dividing the number of recurrent fatal VTEs by all recurrent VTEs. The case-fatality rates were pooled after Freeman–Tukey double arcsine transformation to stabilise variances, using a random effects model according to the method of DERSIMONIAN and LAIRD [15, 16]. Pooled case-fatality rates were reported with corresponding 95% confidence intervals. Subsequently, we estimated the rate of recurrent VTE and fatal recurrent VTE per 100 patient-years. We assessed statistical heterogeneity of exposure effects across the various cohort studies by calculating the I^2 statistic, which depicts the variance of results from study to study beyond (or rather than) chance. Heterogeneity was considered low when I^2 was <25%, intermediate when I^2 was 25–75% and high when I^2 was >75% [17]. Heterogeneity was explored using meta-regression. We evaluated differences across subgroups under the null hypothesis of no differences (Chi-squared distribution with S (number of subgroups) minus 1 degrees of freedom). All analyses were performed using Stata 14.0 (StataCorp, College Station, TX, USA).

Results

Literature search and study selection

The initial search yielded 7647 potentially relevant articles; 586 in Cochrane, 2839 in Embase, 2307 in PubMed and 1915 in Web of Science (figure 1). After the first screening of title and abstract, 7540 records were excluded, leaving 107 unique articles for detailed assessment. An additional 83 articles were excluded after full review for the following reasons: 28 were abstracts only, with insufficient information, 27 comprised studies of duplicate patients with other reports, eight did not clarify if fatal events were on or off anticoagulation treatment, eight had fewer than 100 patients, four did not distinguish between provoked and unprovoked VTE and authors did not comply with our data request after at least two attempts, and eight were excluded for other reasons. The remaining 24 articles all satisfied our predetermined methodological criteria [18–41].

Included studies

Table 1 shows the characteristics of the included studies. 15 were cohort studies [21, 23–26, 28, 29, 32, 33, 35, 37–41] and nine were RCTs [18–20, 22, 27, 30, 31, 34, 36]. The 24 articles were published between 1995 and 2017 and included a total of 8914 patients with unprovoked VTE (range 117–914 patients per study). The median follow-up duration after treatment cessation was 2.5 years (range 1–7.7 years). The evaluation of the presence of bias is shown in table 2. Of the 24 studies, 18 were considered to be at low or moderate risk of bias and were included in the primary analysis. Five studies did not involve an independent adjudication committee [24, 28, 32, 33, 40]. Most studies did not meet the criteria of the ISTH definition of unprovoked VTE [20, 21, 24, 26, 28–30, 32, 34–39, 41]. One study did not provide any definition of unprovoked VTE [22].

Primary outcome: rate of fatal recurrent VTE in studies with low or moderate risk of bias

The 18 studies with low or moderate risk of bias enrolled a total of 6758 patients with a median follow-up of 2.2 years (range 133–914 years). Table 3 shows the rates of recurrent VTE and fatal recurrent VTE per subgroup. The weighted pooled rate of recurrent VTE in studies with low or moderate risk of bias was 6.3 (95% CI 5.4–7.3, I^2=72.6%) per 100 patient-years and the rate of fatal recurrent VTE was 0.17 (95% CI

```
┌──────────────────────────────────────────────────────┐
│ Potentially relevant articles found with search       │
│ strategy (n=7647)                                      │
│   Cochrane (n=586)                                     │
│   Embase (n=2839)                                      │
│   PubMed (n=2037)                                      │
│   Web of Science (n=1915)                              │
└──────────────────────────────────────────────────────┘
           │
           │        ┌──────────────────────────────────────────────────────┐
           │───────▶│ Excluded (n=7540)                                    │
           │        │   Duplicates (n=2431)                                │
           │        │   Not relevant based on title and abstract (n=5109)  │
           │        └──────────────────────────────────────────────────────┘
           ▼
┌──────────────────────────────────────────────────────┐
│ Detailed assessment for eligibility (n=107)           │
└──────────────────────────────────────────────────────┘
           │
           │        ┌──────────────────────────────────────────────────────┐
           │        │ Excluded (n=83)                                      │
           │        │   Abstracts without sufficient information (n=28)    │
           │───────▶│   Duplicate patients (n=27)                          │
           │        │   Unclear if fatal events were on or off treatment (n=8) │
           │        │   <100 patients included (n=8)                       │
           │        │   No distinction between provoked and unprovoked VTE (n=4) │
           │        │   Other reasons (n=8)                                │
           │        └──────────────────────────────────────────────────────┘
           ▼
┌──────────────────────────────────────────────────────┐
│ Included for analysis (n=24)                          │
└──────────────────────────────────────────────────────┘
```

FIGURE 1 Flow chart of the clinical search. VTE: venous thromboembolism.

0.047–0.33, I^2=83.57%) per 100 patient-years, for a case-fatality rate of 2.6% (95% CI 0.86–5.0, I^2=66.6%; figure 2).

Secondary outcomes

The overall weighted pooled fatal rate of VTE recurrence among all 24 studies was 6.2 (95% CI 5.4–7.2, I^2=86.8%) per 100 patient-years and the rate of fatal recurrent VTE was 0.13 (95% CI 0.036–0.25, I^2=72.7%) per 100 patient-years, for a case-fatality rate of 2.0% (95% CI 0.69–3.8, I^2: 65.2%; online supplementary figure S1).

Studies that initiated enrolment before the year 2000 had a numerically higher, but not significantly different, pooled rate of fatal VTE than studies that started inclusion within or after the year 2000 (0.27, 95% CI 0.038–0.59; I^2=83.1 versus 0.039, 95% CI 0.0028–0.1 per 100 patient-years; I^2=0; p=0.70 for interaction), as well as case-fatality rate (3.7%, 95% CI 0.95–7.6%; I^2=76.5 versus 0.71%, 95% CI 0.063–1.8%; I^2=0; p=0.21 for interaction; online supplementary figure S2). Notably, the analysis of the more recent studies showed good homogeneity (both I^2=0) while the results of earlier studies were quite heterogeneous (I^2>75). The rate of fatal recurrent VTE was similar in cohort and RCT studies (0.11, 95% CI 0.009–0.29; I^2=79.5% versus 0.14, 95% CI 0.021–0.33; I^2=49.7% per 100 patient-years; p=0.96 for interaction) and studies with shorter and longer than 2.5 years follow-up duration (0.11, 95% CI 0.018–0.27; I^2=52.4% versus 0.13, 95% CI 0.076–0.35; I^2=81.7% per 100 patient-years; p=0.94 for interaction). Likewise, the case-fatality rates did not differ for cohort and RCT studies (1.7%, 95% CI 0.19–4.2%; I^2=74.6% versus 2.5%, 95% CI 0.69–5.0%; I^2=26.8%; p=0.87 for interaction) as well as for studies with shorter and longer than 2.5 years follow-up duration (2.2%, 95% CI 0.22–5.4%; I^2=76.6% versus 1.8%, 95% CI 0.46–3.8%; I^2=34.9%; p=0.69 for interaction).

In 19 studies, fatal recurrent VTE could be distinguished for patients initially presenting with DVT versus PE [13, 18, 19, 23–25, 27–39, 41]. The case-fatality rates of patients initially presenting with DVT and PE were 2.3% (95% CI 0.52–4.8%, I^2=60.39%) and 0.12% (95% CI 0–1.8%, I^2=34.9%; p=0.57 for interaction; online supplementary figure S3). When focusing on studies with low or moderate risk of bias only, this numerical difference decreased considerably (2.7%, 95% CI 0.50–6.1%; I^2=63.52% versus 1.6%, 95% CI 0–5.7%; I^2=48.43%; p=0.66 for interaction; online supplementary figure S4).

Fatal VTE definition

The definition of fatal VTE varied widely across studies (online supplementary table S1). Only 12 (54%) studies reported a definition of fatal VTE [18, 19, 22, 24, 25, 27, 30, 31, 34, 36–38], of which 11 (92%)

TABLE 1 Characteristics and outcomes of the included studies

First author, year [ref]	Study type	Enrolment period	VTE patients included	DVT patients included	PE patients included	Secondary VTE at baseline	Initial treatment, minimum months	Follow-up after cessation years	Recurrent PE	Recurrent VTE (DVT/PE at presentation)	Fatal VTE (DVT/PE at presentation)
Schulman, 1995 [18]	RCT	1988–1991	289	249	40	0	VKA, 6	2	5	29 (24/5)	3 (2/1)
Agnelli, 2001 [19]	RCT	1995–1998	133	133	0	0	VKA, 3	3.1	3	21 (21/0)	0
Ridker, 2003 [20]	RCT	1998–2002	253			93 (37)	VKA, 3	2.1#	NA	37	2
Baglin, 2003 [21]	Cohort	1997–2002	193			0	VKA, 3	2	NA	32	0
Schulman, 2003 [22]	RCT	1999–2000	611	389	221	98 (16)	VKA, 6	1.5	23	71	3
Cosmi, 2005 [23]	Cohort	1995–2004	400	400	0	0	VKA, 6	1.8¶	15	75 (75/0)	5 (5/0)
Young, 2006 [24]	Cohort	1996–2002	103	103	0	Unclear	VKA, 3	2.9#	NA	26 (26/0)	1 (1/0)
Prandoni, 2007 [25]	Cohort	1991–2003	864	733	131	0	VKA, 6	4.2#¶	NA	268 (240/28)	34 (30/4)
Baglin, 2008 [26]	Cohort	2001–2003	142			0	VKA, 6	3.2¶	NA	28	0
Prandoni, 2009 [27]	RCT	1999–2006	151	151	0	0	VKA, 6	2.8	7	36 (36/0)	3 (3/0)
Poli, 2010 [28]	Cohort	Unclear	161	0	161	0	VKA, 6	3#¶	11	20 (0/20)	0
Siragusa, 2011 [29]	Cohort	1999–2007	409	409	0	0	VKA, 3	1	NA	29 (29/0)	0
Becattini, 2012 [30]	RCT	2004–2010	197	130	67	0	VKA, 6	2¶	14	43 (27/16)	1 (0/1)
Brighton, 2012 [31]	RCT	2003–2011	411	232	175	0	VKA, 3	3.1#¶	NA	73 (40/33)	1 (0/1)
Olié, 2012 [32]	Cohort	2003–2009	583	175	421	0	VKA, 8 (mean)	2.2	NA	74 (21/53)	0
Ribeiro, 2013 [33]	Cohort	2000–2011	117	88	29	0	VKA, 6	3.6#	NA	22 (20/2)	0
Schulman, 2013 [34]	RCT	2006–2010	662	441	213	Unclear	DOAC or VKA, 6	1.5	13	35 (22/13)	0
Galanaud, 2014 [35]	Cohort	2004–2006	173	173	0	0	DOAC or VKA, 3	3	NA	18 (18/0)	2 (2/0)
Couturaud, 2015 [36]	RCT	2007–2012	187	0	187	0	VKA, 6	3.4¶	31	39 (0/39)	0
Kearon, 2015 [37]	Cohort	2008–2012	319	141	178	16 (5)	VKA, 3	2.2#	17	42 (20/22)	1 (0/1)
Rodger, 2016 [38]	Cohort	2001–2006	450	221	229	0	DOAC or VKA, 5	5	NA	161 (105/56)	3 (3/0)
Kyrle, 2016 [39]	Cohort	1992–2008	839	503	336	0	VKA, 7 (mean)	7.7¶	116	259 (151/108)	4 (3/1)
Franco Moreno, 2016 [40]	Cohort	2004–2013	353	83	270	0	VKA, 3	1.8¶	43	65	1
Rodger, 2017 [41]	Cohort	2008–2015	914	260	654	Unclear	DOAC or VKA, 5	1	NA	42 (10/32)	0

Data are presented as n or n (%), unless otherwise stated. VTE: venous thromboembolism; DVT: deep vein thrombosis; PE: pulmonary embolism; RCT: randomised controlled trial; VKA: vitamin K antagonist; NA: not applicable; DOAC: direct oral anticoagulant. #: comprises follow-up of patients with provoked VTE; ¶: median follow-up duration.

TABLE 2 Evaluation of presence of bias for all 24 identified relevant studies

First author, year [ref]	Representative study population			Incomplete outcome data		Selective outcome reporting			Overall judgement
	Clear description of inclusion and exclusion criteria	Patient population[#]	Adequate anticoagulation treatment prior to cessation	Clear follow-up duration	Complete follow-up >95%	Definition of unprovoked VTE[¶]	Definition of fatal VTE	Adjudication of outcomes	Bias in certain direction[+]
Schulman, 1995 [18]	green	yellow	green	green	green	green	green	green	green
Agnelli, 2001 [19]	green	green	green	green	green	green	green	green	green
Ridker, 2003 [20]	green	yellow	green	green	green	yellow	red	green	yellow
Baglin, 2003 [21]	green	yellow	green	green	green	yellow	red	green	yellow
Schulman, 2003 [22]	green	green	green	green	green	red	green	green	yellow
Cosmi, 2005 [23]	green	green	green	green	green	green	red	green	yellow
Young, 2006 [24]	green	red	green	green	red	yellow	green	red	red
Prandoni, 2007 [25]	green	red	green	green	green	green	yellow	green	yellow
Baglin, 2008 [26]	green	yellow	green	green	green	green	red	green	yellow
Prandoni, 2009 [27]	green	green	green	green	green	green	yellow	green	yellow
Poli, 2010 [28]	green	red	green	green	green	yellow	red	red	red
Siragusa, 2011 [29]	green	green	green	green	green	yellow	red	green	yellow
Becattini, 2012 [30]	green	green	green	green	green	yellow	red	green	green
Brighton, 2012 [31]	green	yellow	green	green	green	green	green	green	green
Olié, 2012 [32]	green	green	green	green	red	yellow	red	red	red
Ribeiro, 2013 [33]	green	yellow	green	green	yellow	yellow	red	red	yellow
Schulman, 2013 [34]	green	green	green	green	green	yellow	yellow	green	yellow
Galanaud, 2014 [35]	green	yellow	green	green	green	yellow	red	green	yellow
Couturaud, 2015 [36]	green	green	green	green	green	yellow	yellow	green	yellow
Kearon, 2015 [37]	green	red	green	green	green	yellow	yellow	green	yellow
Rodger, 2016 [38]	green	green	green	green	red	yellow	green	green	yellow
Kyrle, 2016 [39]	green	green	green	green	red	yellow	red	green	red
Franco Moreno, 2016 [40]	green	green	green	green	green	green	red	red	red
Rodger, 2017 [41]	green	yellow	green	green	green	yellow	green	green	yellow

yellow unknown or unclear, red no, green yes, unless otherwise stated. VTE: venous thromboembolism. [#]: yellow other than definitions in our study, red not present, green according to definitions in our study; [¶]: patient selection: red no distinction in follow-up and baseline characteristics between provoked and unprovoked VTE, yellow no distinction in follow-up or baseline characteristics between provoked and unprovoked VTE, green unprovoked VTE patients clearly identified; [+]: yellow moderate risk, red high risk, green low risk.

TABLE 3 Fatal venous thromboembolism (VTE) rates per subgroup

	Studies included	Patients	Fatal recurrent VTE	Recurrent VTE	Pooled case-fatality rate % (95% CI)	I^2 %	Pooled rate of recurrent fatal VTE per 100 patient-years (95% CI)	Pooled rate of recurrent VTE per 100 patient-years (95% CI)
VTE at baseline in studies with low or moderate risk of bias								
Unprovoked VTE	18	6758	58	1079	2.6 (0.86–5.0)	66.60	0.17 (0.047–0.33)	6.3 (5.42–7.3)
Unprovoked DVT	13	3675	45	669	2.7 (0.50–6.1)	63.52	0.18 (0.025–0.43)	6.2 (4.6–8.0)
Unprovoked PE	9	1783	8	243	1.6 (0–5.7)	48.43	0.060 (0–0.28)	5.6 (4.2–7.1)
Other subgroups								
Overall VTE	24	8914	64	1545	2.0 (0.69–3.8)	65.21	0.13 (0.036–0.25)	6.2 (5.4–7.2)
Overall DVT	17	4544	49	887	2.3 (0.52–4.8)	60.39	0.14 (0.022–0.33)	6.3 (5.0–7.6)
Overall PE	13	2730	9	426	0.12 (0–1.8)	34.90	0.011 (0–0.11)	4.9 (4.2–5.7)
Enrolment before 2000	11	4245	55	883	4.0 (1.3–7.8)	76.46	0.27 (0.038–0.59)	6.8 (5.4–8.4)
Enrolment after January 1, 2000	12	4508	9	642	0.71 (0.063–1.8)	0	0.039 (0.0028–0.1)	5.9 (0.47–7.2)
Cohort	16	6020	51	1161	1.7 (0.19–4.2)	74.62	0.11 (0.009–0.29)	6.4 (5.3–7.6)
RCT	9	2894	13	384	2.5 (0.69–5.0)	26.83	0.14 (0.021–0.33)	6.0 (4.6–7.6)
Follow-up ⩽2.5 years	12	5183	16	574	1.8 (0.46–3.8)	34.85	0.11 (0.018–0.27)	6.7 (5.2–8.3)
Follow-up >2.5 years	12	3731	48	971	2.2 (0.22–5.4)	76.57	0.13 (0.076–0.35)	5.8 (4.8–7.0)

Data are presented as n, unless otherwise stated. DVT: deep vein thrombosis; PE: pulmonary embolism; RCT: randomised controlled trial.

First author, year [ref]	Overall CFR	CFR % (95% CI)	Weight %
SCHULMAN, 1995 [18]		10 (3.6–26)	4.68
AGNELLI, 2001 [19]		0 (0–15)	3.96
RIDKER, 2003 [20]		5.4 (1.5–18)	5.23
BAGLIN, 2003 [21]		0 (0–11)	4.91
SCHULMAN, 2003 [22]		4.3 (1.5–12)	6.59
COSMI, 2005 [23]		6.7 (2.9–15)	6.69
PRANDONI, 2007 [25]		13 (9.2–17)	8.33
BAGLIN, 2008 [26]		0 (0–12)	4.60
PRANDONI, 2009 [27]		8.3 (2.9–22)	5.17
SIRAGUSA, 2011 [29]		0 (0–12)	4.68
BECATTINI, 2012 [30]		2.3 (0.41–12)	5.56
BRIGHTON, 2012 [31]		1.4 (0.24–7.4)	6.64
SCHULMAN, 2013 [34]		0 (0–10)	5.11
GALLANAUD, 2014 [35]		11 (3.1–33)	3.62
COUTURAUD, 2015 [36]		0 (0–9.0)	5.35
KEARON, 2015 [37]		2.4 (0.42–12)	5.51
RODGER, 2016 [38]		1.9 (0.64–5.3)	7.83
RODGER, 2017 [41]		0 (0–8.4)	5.51
VTE low to moderate bias (I²=66.60)		2.6 (0.86–5.0)	100

FIGURE 2 Meta-analysis of case-fatality incidences after anticoagulant cessation in studies with low-to-moderate risk of bias. CFR: case-fatality rate; VTE: venous thromboembolism.

included autopsy and/or clinical suspicion [18, 19, 22, 24, 25, 27, 30, 31, 36–38] and five (42%) involved "sudden unexplained death" [25, 27, 34, 36, 37]. Studies including "sudden unexplained death" in their fatal VTE definition were found to have the highest case-fatality rates (3.6%, 95% CI 0.018–11%; I^2=81.15%), while studies without a clear definition of fatal recurrent VTE reported the lowest rates (0.95%, 95% CI 0.067–2.5%; I^2=27.06%; p=0.29 for interaction; online supplementary table S2). This difference in case-fatality rates was observed in both index PE and index DVT patients.

Discussion

In this systematic review and meta-analysis, we determined the risk of fatal recurrent VTE in patients with unprovoked VTE after cessation of anticoagulation treatment. We observed a pooled rate of fatal recurrent VTE of 0.17 per 100 patient-years with a case-fatality rate of 2.6% in studies with low to moderate risk of bias. Where most meta-analyses performed in our study showed relevant heterogeneity among the included studies, the secondary analysis focussing on more recent studies (patient enrolment after January 1, 2000; total of 4508 patients) showed good homogeneity. The numerically lower pooled rate of fatal recurrence (0.039 per 100 patient-years) and case-fatality rate (0.71%) found in this subanalysis may be explained by improved patient care over the years, earlier presentation at the hospital or detection of smaller and less dangerous PE blood clots by more advanced CTPA technology.

The present study revealed similar rates of fatal recurrent VTE in cohort studies compared to RCTs, thus supporting the external validity of our findings. The fatal rates of studies with longer and shorter follow-up durations did not differ as well, indicating that our main finding is valid for long-term follow-up (at least beyond the first 2 years after treatment continuation). Furthermore, we use the finding of a lower rate of fatal recurrent VTE in more recent studies as an argument to hypothesise that the identified rates in our main analysis represent an overestimation of the "true" risk rather than an underestimation. Therefore, our findings provide clinicians, guidelines committees, investigators and policymakers with a solid and valid benchmark of the mortality risk due to recurrent VTE after cessation of treatment to be compared with the risks associated with long-term anticoagulation treatment for patients with unprovoked VTE [4, 5]. Importantly, since risk of VTE recurrence changes over time with the bulk of recurrences

occurring in the first years, and the risk of bleeding remains more stable, the ultimate answer to the question of the most optimal duration of anticoagulation for unprovoked VTE is to be determined in future RCTs with long-term follow-up.

We found a nonsignificant higher risk of fatal recurrent VTE after an index DVT diagnosis than after an index PE diagnosis, which was unexpected [7, 10]. This difference is mostly explained by biases of the data pooling due to major methodological differences between the included studies. Other explanations may be that PE is often overdiagnosed due to adoption of increasingly advanced CT technology [42]. In addition, a selection of "healthier" PE patients for whom anticoagulation discontinuation was deemed to be safe in observational studies could have contributed to the lower observed fatal rates of recurrent VTE. Lastly, many of the patients with DVT may actually have had PE as well, although this was not objectively confirmed and therefore nor reported in the original study publications.

Remarkably, the reported rate of fatal recurrent VTE was largely dependent on the definition adopted across the various studies. Overall, studies without a clear definition reported the lowest rates, while studies in which unexplained death was adjudicated as recurrent VTE showed the highest rates. Half of the included studies did not report a definition of fatal VTE, whereas the remaining studies used various definitions ranging from autopsy findings alone to "sudden unexplained death". With no widely accepted definition of "fatal VTE", it is impossible to rank these different definitions, although it seems reasonable to assume that studies focussing on autopsy findings may provide underestimated rates of fatal recurrent VTE, while the opposite is true for studies adjudicating all unexplained death as being provoked by recurrent VTE. Moreover, the adjudication process itself might also be difficult and could possibly lead to different rates of PE-related deaths among studies. Our findings thus urgently call for an effort to standardise this definition for future studies in order to allow for valid interstudy comparisons [43].

Current guideline recommendations with regard to extended duration of treatment after unprovoked VTE will be confirmed beyond doubt if these studies show that long-term treatment with DOACs is, indeed, associated with a yearly rate of fatal bleeding <0.047–0.33%. Until then, anticoagulation duration should be individualised based on a patient-specific balance between bleeding and recurrent thrombotic risk. Valid bleeding and thrombotic risk tools have been developed and, although not validated in RCTs, could be helpful to assess these risks and thereby identify patients who may benefit from short- or long-term anticoagulation treatment [44–47].

Strong points of this analysis include the strict selection criteria applied and the large number of patients studied. Source data were only derived from high-quality studies. Moreover, we were able to compare fatal rates in four relevant subgroups. Our study has several limitations in addition to the issue of varying definitions of fatal recurrent VTE. In particular, we did not have the availability of patient-level data, which would have allowed us to evaluate the prognostic role of risk factors such as age and sex. In addition, although we performed rigorous inclusion criteria and focused only on high-quality studies, the meta-analyses presented were subject to relevant heterogeneity caused by several between-study differences, especially for those studies that enrolled patients before January 1, 2000.

Conclusions

This meta-analysis revealed a pooled rate of fatal recurrent VTE of 0.17 (95% CI 0.047–0.33) per 100 patient-years for patients with unprovoked VTE after discontinuation of anticoagulation therapy in studies with low to moderate risk of bias. This was consistent with a case-fatality rate of 2.6% (95% CI 0.86–5.0%). Notably, we observed utilisation of varying fatal VTE definitions which was associated with moderate to high between-study heterogeneity, affecting the reported rates of fatal recurrent VTE. Current guideline recommendations on the duration of treatment of unprovoked VTE would be strengthened if future studies show that long-term anticoagulation treatment with DOACs is indeed associated with a rate of fatal bleeding <0.33% per year, representing the upper limit of the 95% confidence interval the pooled incident rate of fatal recurrent VTE after anticoagulation discontinuation.

References

1   Heit JA, Mohr DN, Silverstein MD, *et al.* Predictors of recurrence after deep vein thrombosis and pulmonary embolism: a population-based cohort study. *Arch Intern Med* 2000; 160: 761–768.

2   Prandoni P, Lensing AWA, Cogo A, *et al.* The long-term clinical course of acute deep venous thrombosis. *Ann Intern Med* 1996; 125: 1–7.

3   Boutitie F, Pinede L, Schulman S, *et al.* Influence of preceding length of anticoagulant treatment and initial presentation of venous thromboembolism on risk of recurrence after stopping treatment: analysis of individual participants' data from seven trials. *BMJ* 2011; 342: d3036.

4   Kearon C, Akl EA, Ornelas J, *et al.* Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. *Chest* 2016; 149: 315–352.

5   Konstantinides SV, Torbicki A, Agnelli G, *et al.* 2014 ESC Guidelines on the diagnosis and management of acute pulmonary embolism. *Eur Heart J* 2014; 35: 3033–3069.

6   Klok FA, Kooiman J, Huisman MV, *et al.* Predicting anticoagulant-related bleeding in patients with venous thromboembolism: a clinically oriented review. *Eur Respir J* 2015; 45: 201–210.

7   Carrier M, Le Gal G, Wells PS, *et al.* Systematic review: case-fatality rates of recurrent venous thromboembolism and major bleeding events among patients treated for venous thromboembolism. *Ann Intern Med* 2010; 152: 578–589.

8   Linkins LA, Choi PT, Douketis JD. Clinical impact of bleeding in patients taking oral anticoagulant therapy for venous thromboembolism: a meta-analysis. *Ann Intern Med* 2003; 139: 893–900.

9   van der Hulle T, Kooiman J, den Exter PL, *et al.* Effectiveness and safety of novel oral anticoagulants as compared with vitamin K antagonists in the treatment of acute symptomatic venous thromboembolism: a systematic review and meta-analysis. *J Thromb Haemost* 2014; 12: 320–328.

10   Douketis JD, Kearon C, Bates S, *et al.* Risk of fatal pulmonary embolism in patients with treated venous thromboembolism. *JAMA* 1998; 279: 458–462.

11   Moher D, Liberati A, Tetzlaff J, *et al.* Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *Ann Intern Med* 2009; 151: 264–269.

12   Huisman MV, Klok FA. Diagnostic management of acute deep vein thrombosis and pulmonary embolism. *J Thromb Haemost* 2013; 11: 412–422.

13   Kearon C, Ageno W, Cannegieter SC, *et al.* Categorization of patients as having provoked or unprovoked venous thromboembolism: guidance from the SSC of ISTH. *J Thromb Haemost* 2016; 14: 1480–1483.

14   Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions. Chichester, John Wiley & Sons, 2011.

15   DerSimonian R, Laird N. Meta-analysis in clinical trials. *Control Clin Trials* 1986; 7: 177–188.

16   Freeman MF, Tukey JW. Transformations related to the angular and the square root. *Ann Math Statist* 1950; 21: 607–611.

17   Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. *Stat Med* 2002; 21: 1539–1558.

18   Schulman S, Rhedin AS, Lindmarker P, *et al.* A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism. *N Engl J Med* 1995; 332: 1661–1665.

19   Agnelli G, Prandoni P, Santamaria MG, *et al.* Three months *versus* one year of oral anticoagulant therapy for idiopathic deep venous thrombosis. *N Engl J Med* 2001; 345: 165–169.

20   Ridker PM, Goldhaber SZ, Danielson E, *et al.* Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism. *N Engl J Med* 2003; 348: 1425–1434.

21   Baglin T, Luddington R, Brown K, *et al.* Incidence of recurrent venous thromboembolism in relation to clinical and thrombophilic risk factors: prospective cohort study. *Lancet* 2003; 362: 523–526.

22   Schulman S, Wåhlander K, Lundstrom T, *et al.* Secondary prevention of venous thromboembolism with the oral direct thrombin inhibitor ximelagatran. *N Engl J Med* 2003; 349: 1713–1721.

23   Cosmi B, Legnani C, Cini M, *et al.* D-dimer levels in combination with residual venous obstruction and the risk of recurrence after anticoagulation withdrawal for a first idiopathic deep vein thrombosis. *Thromb Haemost* 2005; 94: 969–974.

24   Young L, Ockelford P, Milne D, *et al.* Post-treatment residual thrombus increases the risk of recurrent deep vein thrombosis and mortality. *J Thromb Haemost* 2006; 4: 1919–1924.

25   Prandoni P, Noventa F, Ghirarduzzi A, *et al.* The risk of recurrent venous thromboembolism after discontinuing anticoagulation in patients with acute proximal deep vein thrombosis or pulmonary embolism. A prospective cohort study in 1,626 patients. *Haematologica* 2007; 92: 199–205.

26   Baglin T, Palmer CR, Luddington R, *et al.* Unprovoked recurrent venous thrombosis: prediction by D-dimer and clinical risk factors. *J Thromb Haemost* 2008; 6: 577–582.

27   Prandoni P, Prins MH, Lensing AW, *et al.* Residual thrombosis on ultrasonography to guide the duration of anticoagulation in patients with deep venous thrombosis: a randomized trial. *Ann Intern Med* 2009; 150: 577–585.

28   Poli D, Grifoni E, Antonucci E, *et al.* Incidence of recurrent venous thromboembolism and of chronic thromboembolic pulmonary hypertension in patients after a first episode of pulmonary embolism. *J Thromb Thrombolys* 2010; 30: 294–299.

29   Siragusa S, Malato A, Saccullo G, *et al.* Residual vein thrombosis for assessing duration of anticoagulation after unprovoked deep vein thrombosis of the lower limbs: the extended DACUS study. *Am J Hematol* 2011; 86: 914–917.

30   Becattini C, Agnelli G, Schenone A, *et al.* Aspirin for preventing the recurrence of venous thromboembolism. *N Engl J Med* 2012; 366: 1959–1967.

31   Brighton TA, Eikelboom JW, Mann K, et al. Low-dose aspirin for preventing recurrent venous thromboembolism. N Engl J Med 2012; 367: 1979–1987.

32   Olié V, Zhu TN, Martinez I, et al. Sex-specific risk factors for recurrent venous thromboembolism. Thromb Res 2012; 130: 16–20.

33   Ribeiro DD, Lijfering WM, Barreto SM, et al. Risk of recurrent venous thrombosis related to past provoking risk situations: follow-up of a cohort study. Blood Coagul Fibrinolysis 2013; 24: 562–566.

34   Schulman S, Kearon C, Kakkar AK, et al. Extended use of dabigatran, warfarin, or placebo in venous thromboembolism. N Engl J Med 2013; 368: 709–718.

35   Galanaud JP, Sevestre MA, Genty C, et al. Incidence and predictors of venous thromboembolism recurrence after a first isolated distal deep vein thrombosis. J Thromb Haemost 2014; 12: 436–443.

36   Couturaud F, Sanchez O, Pernod G, et al. Six months vs extended oral anticoagulation after a first episode of pulmonary embolism: the PADIS-PE randomized clinical trial. JAMA 2015; 314: 31–40.

37   Kearon C, Spencer FA, O'Keeffe D, et al. D-dimer testing to select patients with a first unprovoked venous thromboembolism who can stop anticoagulant therapy: a cohort study. Ann Intern Med 2015; 162: 27–34.

38   Rodger MA, Scarvelis D, Kahn SR, et al. Long-term risk of venous thrombosis after stopping anticoagulants for a first unprovoked event: a multi-national cohort. Thromb Res 2016; 143: 152–158.

39   Kyrle PA, Kammer M, Eischer L, et al. The long-term recurrence risk of patients with unprovoked venous thromboembolism: an observational cohort study. J Thromb Haemost 2016; 14: 2402–2409.

40   Franco Moreno AI, García Navarro MJ, Ortiz Sánchez J, et al. A risk score for prediction of recurrence in patients with unprovoked venous thromboembolism (DAMOVES). Eur J Intern Med 2016; 29: 59–64.

41   Rodger MA, Le Gal G, Anderson DR, et al. Validating the HERDOO2 rule to guide treatment duration for women with unprovoked venous thrombosis: multinational prospective cohort management study. BMJ 2017; 356: j1065.

42   Wiener RS, Schwartz LM, Woloshin S. When a test is too good: how CT pulmonary angiograms find pulmonary emboli that do not need to be found. BMJ 2013; 347: f3368.

43   Girard P, Penaloza A, Parent F, et al. Reproducibility of clinical events adjudications in a trial of venous thromboembolism prevention. J Thromb Haemost 2017; 15: 662–669.

44   Hendriksen JM, Geersing GJ, Lucassen WA, et al. Diagnostic prediction models for suspected pulmonary embolism: systematic review and independent external validation in primary care. BMJ 2015; 351: h4438.

45   Klok FA, Hösel V, Clemens A, et al. Prediction of bleeding events in patients with venous thromboembolism on stable anticoagulation treatment. Eur Respir J 2016; 48: 1369–1376.

46   Klok FA, Barco S, Konstantinides SV. External validation of the VTE-BLEED score for predicting major bleeding in stable anticoagulated patients with venous thromboembolism. Thromb Haemost 2017; 117: 1164–1170.

47   Klok FA, Barco S, Konstantinides SV. Evaluation of VTE-BLEED for predicting intracranial or fatal bleedings in stable anticoagulated patients with venous thromboembolism. Eur Respir J 2018; 51: 1800077.